Leading the March
to IBD Bispecifics

ABOUT CALDERA

Caldera is a clinical stage biotechnology company developing the first-in-class bispecific antibody CLD-423 for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases.

Supported by leading biotech investors Atlas Venture, LAV, venBio, Omega Funds, Wellington Management and Janus Henderson Investors.

Caldera has assembled a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building companies through to successful exits.

Single targeted IBD therapies have hit an efficacy ceiling. Bispecifics are the next horizon of IBD treatment. CLD-423 is a clinical stage bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways. Combining these two powerful autoimmune targets in a single molecule represents the next frontier in IBD treatment.

CLD-423 is rationally designed to achieve a best-in-disease profile with optimized efficacy, safety, pharmacokinetics and developability.

A Phase 1 healthy volunteer trial of CLD-423 is ongoing.

Green hexagonal sticker with a white Y shape antenna icon, black text reads 'CLD-423' and 'Anti IL-23p19 x TL1A'.

CLD-423

LEADERSHIP

Professional portrait of Praveen Tipirneni, MD, MBA Chief Executive Officer of Caldera Therapeutics in a dark suit and light blue shirt against a blurred background.

Praveen Tipirneni, MD, MBA
Chief Executive Officer

Professional portrait of Liangsu Wang, PhD Chief Scientific Officer of Caldera Therapeutics with dark hair, smiling, in a business setting with blurred background.

Liangsu Wang
Chief Scientific Officer

A Professional portrait of Zhong Liu, PhD Chief Technology Officer of Caldera Therapeutics with glasses wearing a dark suit jacket and a white dress shirt standing in a modern, brightly lit corridor.

Zhong Liu
Chief Technology Officer

A professional headshot of Aaron Pelta, MBA Chief Business Officer of Caldera Therapeutics in a dark suit and white shirt with a blurred, light-colored background.

Aaron Pelta
Chief Business Officer

A Professional headshot middle-aged of Colm White Chief Program Officer at Caldera Therapeutics with short brown hair and a beard, wearing glasses, a black blazer, and a red striped dress shirt, smiling in an indoor setting with bright lighting.

Colm White
Chief Program Officer

A professional of Ajay Duggal MBChB, MRCP,DPM Interim Chief Medical Officer at Caldera Therapeutics with dark hair, wearing a white shirt and dark blazer, smiling in a modern indoor setting.

Ajay Duggal
Interim Chief Medical Officer

BOARD OF DIRECTORS

Praveen Tipirneni, Caldera CEO
Michael Gladstone, Atlas Venture
Aaron Royston, venBio
Xiaodi Su, LAV
Michelle Doig, Omega Funds

INVESTORS

Atlas Venture logo
LAV logo
VenBio logo
Logo for Omega Funds with stylized red, black, and gray circular design and the text 'Omega Funds'.
Wellington Management logo with black text on white background.
Logo for Janus Henderson Investors in black and white.

NEWS